Literature DB >> 33688918

Targeting mechanosensitive MDM4 promotes lung fibrosis resolution in aged mice.

Jing Qu1,2, Shan-Zhong Yang1, Yi Zhu1, Ting Guo1,3, Victor J Thannickal1, Yong Zhou1.   

Abstract

Aging is a strong risk factor and an independent prognostic factor for progressive human idiopathic pulmonary fibrosis (IPF). Aged mice develop nonresolving pulmonary fibrosis following lung injury. In this study, we found that mouse double minute 4 homolog (MDM4) is highly expressed in the fibrotic lesions of human IPF and experimental pulmonary fibrosis in aged mice. We identified MDM4 as a matrix stiffness-regulated endogenous inhibitor of p53. Reducing matrix stiffness down-regulates MDM4 expression, resulting in p53 activation in primary lung myofibroblasts isolated from IPF patients. Gain of p53 function activates a gene program that sensitizes lung myofibroblasts to apoptosis and promotes the clearance of apoptotic myofibroblasts by macrophages. Destiffening of the fibrotic lung matrix by targeting nonenzymatic cross-linking or genetic ablation of Mdm4 in lung (myo)fibroblasts activates the Mdm4-p53 pathway and promotes lung fibrosis resolution in aged mice. These findings suggest that mechanosensitive MDM4 is a molecular target with promising therapeutic potential against persistent lung fibrosis associated with aging.
© 2021 Qu et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33688918      PMCID: PMC7953267          DOI: 10.1084/jem.20202033

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  143 in total

1.  Early stages of p53-induced apoptosis are reversible.

Authors:  F J Geske; R Lieberman; R Strange; L E Gerschenson
Journal:  Cell Death Differ       Date:  2001-02       Impact factor: 15.828

2.  Fractalkine-induced MFG-E8 leads to enhanced apoptotic cell clearance by macrophages.

Authors:  Michael Miksa; Dhruv Amin; Rongqian Wu; Thanjavur S Ravikumar; Ping Wang
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

3.  Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine).

Authors:  Jean-Claude Gevrey; Beth M Isaac; Dianne Cox
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

4.  Identification of a factor that links apoptotic cells to phagocytes.

Authors:  Rikinari Hanayama; Masato Tanaka; Keiko Miwa; Azusa Shinohara; Akihiro Iwamatsu; Shigekazu Nagata
Journal:  Nature       Date:  2002-05-09       Impact factor: 49.962

5.  Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.

Authors:  Vivian Barry-Hamilton; Rhyannon Spangler; Derek Marshall; Scott McCauley; Hector M Rodriguez; Miho Oyasu; Amanda Mikels; Maria Vaysberg; Haben Ghermazien; Carol Wai; Carlos A Garcia; Arleene C Velayo; Brett Jorgensen; Donna Biermann; Daniel Tsai; Jennifer Green; Shelly Zaffryar-Eilot; Alison Holzer; Scott Ogg; Dung Thai; Gera Neufeld; Peter Van Vlasselaer; Victoria Smith
Journal:  Nat Med       Date:  2010-09-05       Impact factor: 53.440

6.  The pathogenesis of chronic hypersensitivity pneumonitis in common with idiopathic pulmonary fibrosis: expression of apoptotic markers.

Authors:  Torahiko Jinta; Yasunari Miyazaki; Masato Kishi; Takumi Akashi; Tamiko Takemura; Naohiko Inase; Yasuyuki Yoshizawa
Journal:  Am J Clin Pathol       Date:  2010-10       Impact factor: 2.493

7.  Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages.

Authors:  Elizabeth F Redente; Rebecca C Keith; William Janssen; Peter M Henson; Luis A Ortiz; Gregory P Downey; Donna L Bratton; David W H Riches
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

8.  CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis.

Authors:  Lucy A Truman; Catriona A Ford; Marta Pasikowska; John D Pound; Sarah J Wilkinson; Ingrid E Dumitriu; Lynsey Melville; Lauren A Melrose; Carol Anne Ogden; Robert Nibbs; Gerard Graham; Christophe Combadiere; Christopher D Gregory
Journal:  Blood       Date:  2008-09-17       Impact factor: 22.113

9.  Chebulic acid prevents hepatic fibrosis induced by advanced glycation end-products in LX-2 cell by modulating Nrf2 translocation via ERK pathway.

Authors:  Yun-Chang Koo; Min Cheol Pyo; Mi-Hyun Nam; Chung-Oui Hong; Sung-Yong Yang; Kwang-Won Lee
Journal:  Toxicol In Vitro       Date:  2016-03-25       Impact factor: 3.500

10.  Mechanosensing by the α6-integrin confers an invasive fibroblast phenotype and mediates lung fibrosis.

Authors:  Huaping Chen; Jing Qu; Xiangwei Huang; Ashish Kurundkar; Lanyan Zhu; Naiheng Yang; Aida Venado; Qiang Ding; Gang Liu; Veena B Antony; Victor J Thannickal; Yong Zhou
Journal:  Nat Commun       Date:  2016-08-18       Impact factor: 14.919

View more
  4 in total

Review 1.  Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis.

Authors:  Qianru Mei; Zhe Liu; He Zuo; Zhenhua Yang; Jing Qu
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

2.  Transcriptional analysis of lung fibroblasts identifies PIM1 signaling as a driver of aging-associated persistent fibrosis.

Authors:  Tho X Pham; Jisu Lee; Jiazhen Guan; Nunzia Caporarello; Jeffrey A Meridew; Dakota L Jones; Qi Tan; Steven K Huang; Daniel J Tschumperlin; Giovanni Ligresti
Journal:  JCI Insight       Date:  2022-03-22

Review 3.  Stem cells, cell therapies, and bioengineering in lung biology and disease 2021.

Authors:  Laertis Ikonomou; Mattias Magnusson; Ruben Dries; Erica L Herzog; Robert E Hynds; Zea Borok; Jin-Ah Park; Steven Skolasinski; Janette K Burgess; Leigh Turner; Sarah M Mojarad; John E Mahoney; Thomas Lynch; Mareike Lehmann; Victor J Thannickal; Jamie L Hook; Andrew E Vaughan; Evan T Hoffman; Daniel J Weiss; Amy L Ryan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-06-28       Impact factor: 6.011

Review 4.  The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease.

Authors:  Gonçalo Boleto; Jérôme Avouac; Yannick Allanore
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-01-29       Impact factor: 3.625

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.